Toll Like Receptor 8 - Pipeline Review, H1 2020

January 2020 | 84 pages | ID: T372E5610BF0EN
Global Markets Direct

Abstracts

Toll Like Receptor 8 - Pipeline Review, H1 2020

SUMMARY

Toll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

Toll Like Receptor 8 (CD288 or TLR8) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 8 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Melanoma, Solid Tumor, Autoimmune Disorders, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Systemic Lupus Erythematosus, Adenoid Cystic Carcinoma (ACC), Arthritis, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Hepatitis B, Hepatocellular Carcinoma, Inflammation, Leukemia, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Osteoarthritis, Peritoneal Cancer, Rabies, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Triple-Negative Breast Cancer (TNBC).

The latest report Toll Like Receptor 8 - Pipeline Review, H1 2020, outlays comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
• The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
• The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
Altimmune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
ALT-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-8102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DN-1508052 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6742 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INGMM-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JB-6121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugates to Agonize TLR7 and TLR8 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Altimmune Inc, H1 2020
Pipeline by Ascendis Pharma A/S, H1 2020
Pipeline by BioNTech SE, H1 2020
Pipeline by Bolt Biotherapeutics Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Curebiotech Inc, H1 2020
Pipeline by Curevac AG, H1 2020
Pipeline by Dynavax Technologies Corp, H1 2020
Pipeline by Eisai Co Ltd, H1 2020
Pipeline by Galderma SA, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by IngenoVax LLC, H1 2020
Pipeline by Janus Biotherapeutics Inc, H1 2020
Pipeline by Nektar Therapeutics, H1 2020
Pipeline by Seven and Eight Biopharmaceuticals Corp, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by Silverback Therapeutics Inc, H1 2020
Pipeline by Vaccex Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Altimmune Inc
Ascendis Pharma A/S
BioNTech SE
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Nektar Therapeutics
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Silverback Therapeutics Inc
Vaccex Inc